Grant M. Gallagher

Martin Kulldorff, PhD, explains the standard Sweden uses to collect data on the country's seemingly high COVID-19 mortality.

The latest Ebola outbreak in western Democratic Republic of Congo has led to at least 100 cases as of Friday, according to WHO.

Martin Kulldorff, PhD, explains how an age-based focus for COVID-19 mitigation might better protect both older people and younger people with comorbidities.

School administrators, nurses and teachers are trying to develop plans to bring students back for critical in-school learning while keeping staff and immune-suppressed students safe.

Rodney E. Rohde, a clinical laboratory specialist at Texas State University, goes into the competing priorities of college and K-12 school reopening.

Scientists are willing to speak out and have collegial debates – but medical institutions and media have to catch up: fringe voices are often the only ones platformed to discuss important scientific nuances or debates.

A University of Maryland Professor of Pathology explains that SARS-CoV-2 has unique ways of evading detection.

Robert H. Christenson, PhD, describes the threat of AMR and the role of relevant diagnostics in clinical settings.

The US FDA was said to be considering an emergency authorization for COVID-19 plasma just last week. For now, the authorization is on hold.

Citing the rise of the anti-vaccine movement, Peter Hotez, MD, PhD, explains the role scientists can play in building trust and literacy by engaging the public.

Rodney E. Rohde, PhD, a clinical laboratory scientist, helps break down how carefully EUA releases need to be read in order for the public and for scientists from other fields to parse them for useful information.

The ideal time to act on COVID-19 was in January, says public health expert Raj Bhopal.

The US CDC has been engaged in a back and forth with media for several days after reductionist reporting on immunity related to COVID-19 suggested categorical proof of antibody based immunity to reinfection.

SalivaDirect is unique in that it does not require a particular type of swab or collection device; any sterile container is suitable for saliva collection with the test.

The FDA regularly posts updates on recalls, outbreak investigations, and related regulatory activities. Weekly, we identify which of those announcements might be most clinically relevant.

Armand Balboni, MD, PhD, discusses progress toward FDA authorization and/or approval of favipiravir for COVID-19 as a prophylactic measure.

In testing, fingolimod blocked cell-free and cell-to-cell transmission of HIV, reducing latent virus.

Walter A. Orenstein, MD, answers audience questions collected during our Vaccine Race webinar.

How can we bridge the divide between the public and public health? Raj Bhopal argues for a strong but supportive pandemic response.

Administration of the investigational oral microbiome therapeutic SER-109 resulted in a statistically significant decrease in the proportion of patients who had C diff recurrence within 8 weeks of administration versus placebo.

The antiviral is currently emergency authorized for treatment of severe COVID-19.

The authorization is for an amplicon-based next-generation sequencing test from Helix.

The FDA has continued taking various hand sanitizers contaminated with methanol off the market.

Also featuring the latest FDA and global drug development pipeline news.

Raj Bhopal, BSc MD, MPH, addresses the nuances of competing ethical priorities societies face amid COVID-19, alongside political battles and terms like “herd immunity.”

Dovato can now be used as a complete regimen for treatment of HIV-1 infection to replace an existing ART regimen in adults who are virologically suppressed.

Patrick Soon-Shiong and Dr. Adam Brufsky have an open minded discussion on the dangers and potential lessons of the course Swedish health officials recommended the country take over the SARS-CoV-2 pandemic.

Will screening be based on symptoms alone? How accurate and fast must tests be?

The letter was penned by IDSA President Thomas M. File, Jr., MD, MSc, FIDSA and HIVMA Chair Judith Feinberg, MD, FIDSA on behalf of their organizations.

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.